vimarsana.com

Page 79 - தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |Phoenix Group Hldgs Announcements | Phoenix Group Hldgs: Total Voting Rights

A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;

Global Blood Therapeutics (GBT) Q4 2020 Earnings Call Transcript

Operator Greetings, and welcome to Global Blood Therapeutics conference call. [Operator instructions] As a reminder, this conference is being recorded. I would now like to turn this conference over to Mr. Steven Immergut. Please go ahead, sir. You may begin. Steven Immergut Senior Vice President, Head of Corporate Communications, and Investor Relations Thank you, and welcome to GBT s conference call to discuss the company s financial results for the fourth-quarter and full-year 2020 and to provide a business update. I m Steven Immergut, head of communications and investor relations. Joining me on the call are Dr. Ted Love, our president and CEO, who will provide a high-level update on our progress in the fourth quarter and over the full-year 2020; jeff Farrow, our chief financial officer, who will provide an overview of our financial results; and David Johnson, or DJ, our chief commercial officer, who will give an update on the Oxbryta launch.

Median Technologies: Median Strengthens its iBiopsy Leadership Team With the Appointment of Thomas Bonnefont as Chief Operating and Commercial Officer and the Appointment of Mike Doherty as Sr Strategy Advisor, Product Development

(2) These two appointments follow a series of first successful achievements for iBiopsy in 2020 and early 2021. Median prepares to launch its iBiopsy product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy operations globally. Regulatory News: Thomas Bonnefont (Photo: Median Technologies) Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today the appointment of Thomas Bonnefont to the newly created position of Chief Operating and Commercial Officer of the iBiopsy Business Unit as well as the appointment of Mike Doherty as Sr. Strategy Advisor, iBiopsy Product Development. They both join Median s executive team. Mike Doherty is based in the US.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.